Resectable pancreatic head adenocarcinoma: Is R0 resection an illusion? Genetic evaluation of venous resection margin affirmed unrecognized disease

J Visc Surg. 2017 Oct;154(5):329-333. doi: 10.1016/j.jviscsurg.2017.05.009. Epub 2017 Aug 23.

Abstract

Purpose: To assess the K-ras gene mutation in the histologically negative venous margin of a pancreaticoduodenectomy (PD) specimen and its impact on survival.

Method: From 2007 to 2010, 22 patients underwent R0 PD for resecable pancreatic adenocarcinoma. All specimens were stained and the portal vein (PV) bed was identified by blue ink; a 2mm3 sample (including the blue ink) was cut from a microscopic free-tumor block. DNA was extracted and assessed by quantitative real time polymerase chain reaction to detect the K-ras gene mutation. Twelve specimens (55%) (kras+ group) were identified with a K-ras mutation in the venous margin resection, and 10 specimens (kras- group) did not have K-ras mutation detected in the venous margin resection.

Results: The two groups were comparable. Overall 3years survival of patients of kras+ group versus patients of kras- group was 0 and 17% (P=0.03), respectively. Median survival time of patients of kras+ group versus patients of kras- group was 16months vs 25months (P=0.04; 95% confidence interval [1,11-1,88]), respectively.

Conclusion: Genetic evaluation of venous resection margin affirmed unrecognized disease with strong impact on survival in more than 50% of patients with histologically R0 resection.

Keywords: K-ras gene mutation; Margins; Pancreatic cancer.

Publication types

  • Comparative Study

MeSH terms

  • Adenocarcinoma / genetics
  • Adenocarcinoma / mortality
  • Adenocarcinoma / pathology
  • Adenocarcinoma / surgery*
  • Adult
  • Aged
  • Cohort Studies
  • Disease-Free Survival
  • Female
  • Gene Expression Regulation*
  • Humans
  • Male
  • Margins of Excision*
  • Mesenteric Veins / surgery
  • Middle Aged
  • Mutation / genetics
  • Neoplasm Grading
  • Pancreatic Neoplasms / genetics
  • Pancreatic Neoplasms / mortality
  • Pancreatic Neoplasms / pathology
  • Pancreatic Neoplasms / surgery*
  • Pancreaticoduodenectomy / methods
  • Pancreaticoduodenectomy / mortality
  • Portal Vein / surgery
  • Prognosis
  • Proto-Oncogene Proteins p21(ras) / genetics*
  • Retrospective Studies
  • Risk Assessment
  • Survival Analysis
  • Treatment Outcome

Substances

  • KRAS protein, human
  • Proto-Oncogene Proteins p21(ras)